{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:59:45Z","timestamp":1764403185575,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The goal of HCV treatment is eradication of the virus to prevent complications associated with the disease and decrease all-cause mortality. This work compared sustained viral response (SVR) 12\u00a0weeks after end of treatment of chronic HCV patients with different treatment regimens, namely 4 regimens. Two hundred treatment naive chronic HCV patients were selected and divided into 4 equal groups as follows: group A received pegylated interferon (peg IFN) and ribavirin (RBV); group B received peg IFN, RBV, and sofosbuvir (SOF); group C received RBV and SOF; group D received SOF, daclatasvir (DCV), and RBV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The sustained viral response after 12\u00a0months of treatment is 57.23%, 72.09%, 64.40%, and 96.42% of patients in groups A, B, C, and D, respectively. Hence, group D regimen showed the best results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SOF and DCV and RBV have the highest SVR12 and least side effects compared to other treatment regimens. Although group D patients initially had poor pretreatment investigations relative to other groups, they proved to have the highest tolerability to this regimen. Such findings hold promising line of treatment and better prognosis even for chronic HCV patients with poor liver condition.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11845-022-03120-9","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T08:03:07Z","timestamp":1661846587000},"page":"1129-1135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual versus triple therapy in treatment of hepatitis C virus (HCV)"],"prefix":"10.1007","volume":"192","author":[{"given":"Nevine","family":"Bishai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid el","family":"Nabawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed El","family":"Fiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nouman El","family":"Garem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"issue":"06","key":"3120_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3855\/jidc.9784","volume":"12","author":"FA Amer","year":"2018","unstructured":"Amer FA (2018) Large-scale hepatitis C combating campaigns in Egypt and Georgia; past, current and future challenges. J Infection in Developing Countries 12(06):404\u2013414","journal-title":"J Infection in Developing Countries"},{"key":"3120_CR2","first-page":"104","volume":"25","author":"C Reker","year":"2014","unstructured":"Reker C, Islam KM (2014) Risk factors associated with high prevalence rates of hepatitis C infection in Egypt. Int J Infect Dis: IJID: Official Pub Int Soc Infects Dis 25:104\u2013106","journal-title":"Int J Infect Dis: IJID: Official Pub Int Soc Infects Dis"},{"key":"3120_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jvh.12253","volume":"21","author":"G Dore","year":"2014","unstructured":"Dore G, Ward J, Thursz M (2014) Hepatitis C disease burden and strategies to manage the burden. J Viral Hepatitis 21:1\u20134","journal-title":"J Viral Hepatitis"},{"key":"3120_CR4","doi-asserted-by":"crossref","unstructured":"AU J, Pockros P (2014) Novel therapeutic approaches for hepatitis C. Clinical Pharmacol Ther\u00a095(1):78\u201388","DOI":"10.1038\/clpt.2013.206"},{"issue":"1","key":"3120_CR5","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41598-017-17936-4","volume":"8","author":"SP Kouyoumjian","year":"2018","unstructured":"Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ (2018) Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep 8(1):1661","journal-title":"Sci Rep"},{"issue":"4","key":"3120_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ecl.2007.07.001","volume":"36","author":"Y Tomer","year":"2007","unstructured":"Tomer Y, Blackard JT, Akeno N (2007) Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 36(4):1051\u20131066. https:\/\/doi.org\/10.1016\/j.ecl.2007.07.001","journal-title":"Endocrinol Metab Clin North Am"},{"key":"3120_CR7","doi-asserted-by":"publisher","unstructured":"Sonnenblick M, Rosin A (1991) Cardiotoxicity of interferon. A review of 44 cases. Chest\u00a099(3):557\u2013561. https:\/\/doi.org\/10.1378\/chest.99.3.557","DOI":"10.1378\/chest.99.3.557"},{"key":"3120_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1440-1746.2008.05503.x","volume":"24","author":"W Chehadeh","year":"2009","unstructured":"Chehadeh W, Abdella N et al (2009) Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection. J Gastroenterol Hepatol 24:42\u201348","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"3120_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/hep.23340","volume":"51","author":"S Bruno","year":"2010","unstructured":"Bruno S, Shiffman M et al (2010) Efficacy and safety of peg interferon alpha-2a (40KD) plus ribavirin in hepatitis C patients with advance fibrosis and cirrhosis. Hepatology 51(2):388\u2013397","journal-title":"Hepatology"},{"issue":"6","key":"3120_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/gut.48.6.843","volume":"48","author":"A Gramenzi","year":"2001","unstructured":"Gramenzi A, Andreone P et al (2001) Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 48(6):843\u2013848","journal-title":"Gut"},{"key":"3120_CR11","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","volume":"139","author":"M Swain","year":"2010","unstructured":"Swain M, Lai M et al (2010) A sustained virologic response is durable in patients with chronic hepatitis C treated with peg interferon alpha-2a and ribavirin. Gastroenterology 139:1593\u20131601","journal-title":"Gastroenterology"},{"issue":"6","key":"3120_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.5694\/j.1326-5377.2003.tb05192.x","volume":"178","author":"D Kumar","year":"2003","unstructured":"Kumar D et al (2003) Effectiveness of IFN\u03b1-2b\/ribavirin combination therapy for chronic hepatitis C in a clinic setting. Med J Aust 178(6):267\u2013271","journal-title":"Med J Aust"},{"issue":"4","key":"3120_CR13","first-page":"655","volume":"72","author":"RP Ward","year":"2005","unstructured":"Ward RP, Kugelmas M (2005) Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Physician 72(4):655\u2013662","journal-title":"Am Fam Physician"},{"key":"3120_CR14","doi-asserted-by":"publisher","unstructured":"Kemp W, Roberts S (2011) Pegylated interferon and ribavirin for the treatment of chronic hepatitis C. Clin Med Insights: Ther 3:CMT.S4015. https:\/\/doi.org\/10.4137\/CMT.S4015","DOI":"10.4137\/CMT.S4015"},{"issue":"4","key":"3120_CR15","first-page":"120","volume":"4","author":"M Elmashad","year":"2017","unstructured":"Elmashad M, Elsherif A et al (2017) Comparative study between peg IFN based regimen (peg-IFN\/sofosbuvir\/ribavirin) and peg IFN free regimens (sofosbuvir\/simprevir)-(sofosbuvir\/ribavirin) in Egyptian patients with chronic HCV infection. Eur J Pharm Med Res 4(4):120\u2013127","journal-title":"Eur J Pharm Med Res"},{"key":"3120_CR16","doi-asserted-by":"crossref","unstructured":"Dolatimehr F, Haron-Sari et al (2017) Combination of sofosbuvir, pegylated interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systemic review and metaanalysis. DARU J Pharm Sci\u00a025:11","DOI":"10.1186\/s40199-017-0177-x"},{"issue":"9883","key":"3120_CR17","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","volume":"381","author":"KV Kowdley","year":"2013","unstructured":"Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM (2013) Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet (London, England) 381(9883):2100\u20132107. https:\/\/doi.org\/10.1016\/S0140-6736(13)60247-0","journal-title":"Lancet (London, England)"},{"issue":"3","key":"3120_CR18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jhep.2015.04.023","volume":"63","author":"W Doss","year":"2015","unstructured":"Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, Samir W, Hammad R, Kersey K, Jiang D, Doehle B, Knox SJ, Massetto B, McHutchison JG, Esmat G (2015) Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 63(3):581\u2013585. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.023","journal-title":"J Hepatol"},{"key":"3120_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4236\/ojgas.2017.71002","volume":"7","author":"A Aboud","year":"2017","unstructured":"Aboud A (2017) Study of the efficacy of triple therapy of sofosbuvir; pegylated IFN alpha 2a and ribavirin in treatment of chronic hepatitis patients genotype 4 with high fibrosis. Open J Gastroenterol 7:5\u201317","journal-title":"Open J Gastroenterol"},{"key":"3120_CR20","doi-asserted-by":"crossref","unstructured":"Welzel TM, Peterson J, Et Al. Daclatasvir plus sofosbuvir, with or without ribavirin achieved high SVR rates in patients with HCV infection and advanced liver disease in a real-world cohort. GUT 2016.","DOI":"10.1136\/gutjnl-2016-312444"},{"key":"3120_CR21","first-page":"1","volume":"27","author":"C Evangelos","year":"2014","unstructured":"Evangelos C (2014) Papatheodoridis et al, Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol 27:1\u20137","journal-title":"Ann Gastroenterol"},{"key":"3120_CR22","unstructured":"EASL recommendations on treatment of hepatitis C 2016. J Hepatol\u00a0Xxx:5"},{"key":"3120_CR23","doi-asserted-by":"crossref","unstructured":"Fontaine H, Hezode C et al (2015) Efficacy of the oral sofosbuvir-based combination in HCV genotype 4 mono-infected patients for the french observational cohort ANRS Co22 HEPATHER. Abstract LP 28 Presented At The 50th\u00a0Annual Meeting Of The European Association For The Study Of The Liver; Vienna","DOI":"10.1016\/S0168-8278(15)30182-3"},{"key":"3120_CR24","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/hep.23444","volume":"51","author":"M Martinot-Peignoux","year":"2010","unstructured":"Martinot-Peignoux M, Stern C et al (2010) Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the sustained virological response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 51:1121\u20131126","journal-title":"Hepatology"},{"issue":"38","key":"3120_CR25","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.3748\/wjg.v24.i38.4330","volume":"24","author":"D Omran","year":"2018","unstructured":"Omran D, Alboraie M, Zayed RA, Wifi M-N, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M (2018) Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 24(38):4330\u20134340","journal-title":"World J Gastroenterol"},{"issue":"3","key":"3120_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS et al (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. NEJM 370(3):211\u2013221","journal-title":"NEJM"},{"key":"3120_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hep.27366","volume":"61","author":"E Yoshida","year":"2015","unstructured":"Yoshida E, Sulkowski M et al (2015) Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir containing regimens for hepatitis C virus. J Hepatol 61:41\u201345","journal-title":"J Hepatol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-022-03120-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-022-03120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T07:16:30Z","timestamp":1686208590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-022-03120-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3120"],"URL":"https:\/\/doi.org\/10.1007\/s11845-022-03120-9","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}